Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

Bortezomib (BZM) is the first proteasome inhibitor approved for relapsed Mantle Cell Lymphoma (MCL) with durable responses seen in 30%–50% of patients. Given that a large proportion of patients will not respond, BZM resistance is a significant barrier to use this agent in MCL. We hypothesized that a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Leshchenko, Violetta V., Kuo, Pei-Yu, Jiang, Zewei, Weniger, Marc A., Overbey, Jessica, Dunleavy, Kieron, Wilson, Wyndham H., Wiestner, Adrian, Parekh, Samir
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694993/
https://ncbi.nlm.nih.gov/pubmed/25714012
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi